Mark Milton
- Pharmacology top 5%
- Pharmacogenetics and Drug Metabolism 6
- Oncology top 10%
- CAR-T cell therapy research 7
- Drug Transport and Resistance Mechanisms 7
-
- Biosimilars and Bioanalytical Methods 5
-
- Monoclonal and Polyclonal Antibodies Research 7
-
- Peroxisome Proliferator-Activated Receptors 3
-
- Virus-based gene therapy research 4
-
- Retinal Diseases and Treatments 3
- Co-authors
- Patrick MullerChristopher HorvathCindy Q. XiaLiang‐Shang GanMatthew D. SilvaSudeep ChandraPeter J. WorlandShenghua Wen
- Cited by
- PharmacologyOncologyImmunology
- Journals
- The AAPS Journal (4 papers)Regulatory Toxicology and Pharmacology (3 papers)Nature reviews. Immunology (2 papers)
- Partner nations
- United StatesSwitzerlandUnited Kingdom
In The Last Decade
Mark Milton
33 papers receiving 1.2k citations
Hit Papers
Peers
Comparison fields: 5 of 121
- Pharmacology 141
- Oncology 381
- Immunology 212
- Radiology, Nuclear Medicine and Imaging 210
- Molecular Biology 516
Countries citing papers authored by Mark Milton
This map shows the geographic impact of Mark Milton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Milton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Milton more than expected).
Fields of papers citing papers by Mark Milton
This network shows the impact of papers produced by Mark Milton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Milton. The network helps show where Mark Milton may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark Milton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 11 | |
| 2 | 2023 | 0 | |
| 3 | 2023 | 18 | |
| 4 | 2022 | 28 | |
| 5 | 2021 | 20 | |
| 6 | 2021 | 32 | |
| 7 | 2020 | 35 | |
| 8 | 2018 | 9 | |
| 9 | 2017 | 25 | |
| 10 | 2015 | 17 | |
| 11 | Anti-C5 mAb: In Vivo Effects Following Intravitreal Administration to Cynomolgus Monkeys | 2014 | 0 |
| 12 | The determination and interpretation of the therapeutic index in drug developmentbreakdown → | 2012 | 400 |
| 13 | 2010 | 43 | |
| 14 | 2008 | 37 | |
| 15 | 2007 | 71 | |
| 16 | 2004 | 124 | |
| 17 | 2004 | 7 | |
| 18 | 2003 | 2 | |
| 19 | 1990 | 52 | |
| 20 | 1988 | 33 |
About Mark Milton
Mark Milton is a scholar working on Pharmacology, Oncology and Ophthalmology, having authored 36 papers that have together received 1.2k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (7 papers), CAR-T cell therapy research (7 papers), Drug Transport and Resistance Mechanisms (7 papers), Pharmacogenetics and Drug Metabolism (6 papers), Biosimilars and Bioanalytical Methods (5 papers), Virus-based gene therapy research (4 papers), Retinal Diseases and Treatments (3 papers) and Peroxisome Proliferator-Activated Receptors (3 papers). The work is most often cited by research in Pharmacology (141 citations), Oncology (381 citations) and Immunology (212 citations). Mark Milton has collaborated with scholars based in United States, Switzerland and United Kingdom. Frequent co-authors include Patrick Muller, Christopher Horvath, Cindy Q. Xia, Liang‐Shang Gan, Matthew D. Silva, Sudeep Chandra, Peter J. Worland, Shenghua Wen, Michael D. Henry and Jennifer Sims. Their work appears in journals such as The AAPS Journal, Regulatory Toxicology and Pharmacology, Nature reviews. Immunology, Molecular Therapy — Methods & Clinical Development and Biochemical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.